VAERS Explorer
Back to explore

Report #2825438

Received Feb 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
70 yrs
State
CA
Recovered
Not recovered
Vaccinated
Nov 27, 2024
Onset
Nov 27, 2024
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (AREXVY)GLAXOSMITHKLINE BIOLOGICALS1UNKLA

Symptoms (1)

Bursitis

Symptom narrative

Bursitis was reported as worsened; This non-serious case was reported by a physician via sales rep and described the occurrence of bursitis in a 70-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On 27-NOV-2024, the patient received the 1st dose of Arexvy (left arm). On 27-NOV-2024, less than a day after receiving Arexvy, the patient experienced bursitis (Verbatim: Bursitis was reported as worsened). The outcome of the bursitis was not resolved. The reporter considered the bursitis to be related to Arexvy. The company considered the bursitis to be related to Arexvy. Additional Information: GSK Receipt Date: 03-FEB-2025 The patient received Arexvy vaccine and experienced bursitis.; Sender's Comments: US-GSK-US2023145295:same reporter US-GSK-US2023056053:same reporter US-GSK-US2021AMR103016:same reporter US-GSK-US2020AMR210194:same reporter US-GSK-US2020AMR210190:same reporter US-GLAXOSMITHKLINE-US2020AMR089276:same reporter US-GLAXOSMITHKLINE-US2020AMR083961:same reporter